N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients

被引:29
作者
Barrios, V
Calderón, A
Navarro-Cid, J
Lahera, V
Ruilope, LM
机构
[1] Hosp Ramon y Cajal, Dept Cardiol, ES-28034 Madrid, Spain
[2] Rosa de Luxemburgo, Area Primary Care Med 5, Madrid, Spain
[3] Univ Complutense, Sch Med, Dept Physiol, E-28040 Madrid, Spain
[4] Hosp 12 Octubre, Hypertens Unit, E-28041 Madrid, Spain
关键词
ACE inhibitors; hypertension; N-acetylcysteine; nitric oxide; smoking;
D O I
10.1080/08037050213760
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Sulfhydryl group donors, such as N-acetylcysteine (NAC), may enhance the antihypertensive effect of some drugs through a nitric oxide (NO) mechanism. It has been observed that the hypotensive effect of angiotensin-converting enzyme inhibitors (ACEIs) is, at least partially, mediated by NO. We performed a within patient crossover study with the aim to investigate the potential effect of NAC on the ACEI antihypertensive action, via an NO-dependent mechanism. We studied 18 smoker (>10 years of habit and >10 cigarettes daily) hypertensive patients (15 males and three females, aged 69 +/- 5 years) on ACEI therapy (11 captopril and seven enalapril). Patients were randomly allocated to two treatment arms. In one arm, the patients (n = 10) initially received the addition of NAC (600 mg t.i.d.) to the ACEI regimen. In the other group (n = 8), the patients remained only on ACEI. After 21 days, the therapeutic patterns were crossed. The first group received only ACEI, and the second group received ACEI and NAC and completed other 21-day treatment period. We evaluate the effect of NAC on each patient by ambulatory blood pressure monitoring (ABPM), performed at the end of each therapeutic regimen. A significant decrease in systolic and diastolic 24-h blood pressure (24 hBP) and daytime BP (dtBP) was achieved with the combination of ACEI and NAC (ACEI + NAC) when compared to the period with only ACEI: 24 hBP = 146.1 +/- 4.2 vs 137 +/- 3.1 (p < 0.05) and 89.2 ± 2.8 vs 83.5 ± 3.7 mmHg (p = 0.01). DtBP: 149.7 ± 5.6 vs 141 ± 3.7 and 92.1 ± 4 vs 86 ± 3.2 (both, p < 0.05). No significant difference was observed in night-time BP (ntBP). The NAC effect was not statistically different for the two ACEIs. In conclusion, the addition of NAC to an ACEI potentiates its antihypertensive effect during 24hBP and dtBP in smoker hypertensives. This effect may be mediated by an NO-dependent mechanism, probably through the protective effect of NAC on NO oxidation.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 36 条
[1]   KININS, NITRIC-OXIDE, AND THE HYPOTENSIVE EFFECT OF CAPTOPRIL AND RAMIPRILAT IN HYPERTENSION [J].
CACHOFEIRO, V ;
SAKAKIBARA, T ;
NASJLETTI, A .
HYPERTENSION, 1992, 19 (02) :138-145
[2]   INHIBITION AND STIMULATION OF NITRIC-OXIDE SYNTHESIS IN THE HUMAN FOREARM ARTERIAL BED OF PATIENTS WITH INSULIN-DEPENDENT DIABETES [J].
CALVER, A ;
COLLIER, J ;
VALLANCE, P .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) :2548-2554
[3]   THE ROLE OF NITRIC-OXIDE IN ENDOTHELIUM-DEPENDENT VASODILATION OF HYPERCHOLESTEROLEMIC PATIENTS [J].
CASINO, PR ;
KILCOYNE, CM ;
QUYYUMI, AA ;
HOEG, JM ;
PANZA, JA .
CIRCULATION, 1993, 88 (06) :2541-2547
[4]  
CHONG S, 1991, BIOCHEM PHARMACOL, V42, P1433
[5]   IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION OF FOREARM RESISTANCE VESSELS IN HYPERCHOLESTEROLEMIA [J].
CHOWIENCZYK, PJ ;
WATTS, GF ;
COCKCROFT, JR ;
RITTER, JM .
LANCET, 1992, 340 (8833) :1430-1432
[6]   PRESERVED ENDOTHELIUM-DEPENDENT VASODILATATION IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].
COCKCROFT, JR ;
CHOWIENCZYK, PJ ;
BENJAMIN, N ;
RITTER, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (15) :1036-1040
[7]   IMPAIRED VASODILATION OF FOREARM RESISTANCE VESSELS IN HYPERCHOLESTEROLEMIC HUMANS [J].
CREAGER, MA ;
COOKE, JP ;
MENDELSOHN, ME ;
GALLAGHER, SJ ;
COLEMAN, SM ;
LOSCALZO, J ;
DZAU, VJ .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (01) :228-234
[8]  
Deng YB, 1999, CLIN CARDIOL, V22, P705
[9]   Endothelial dysfunction and hypertension [J].
Ferro, CJ ;
Webb, DJ .
DRUGS, 1997, 53 (Suppl 1) :30-41
[10]  
FUNG HL, 1988, J PHARMACOL EXP THER, V245, P524